COVID-19 in Italian patients with rheumatic autoimmune systemic diseases
| Autor: | Ferri, C., Giuggioli, D., Raimondo, V., Fallahi, P., Antonelli, A., Spinella, A., Brittelli, R., Aiello, V., Caminiti, R., L'Andolina, M., Tavoni, A., Bilia, S., Giannini, D., Mariano, G. P., Cecchetti, R., Guiducci, S., Bellando-Randone, S., Ursini, F., Brusi, V., Meliconi, R., Caminiti, M., Varcasia, G., Ferrari, T., Gigliotti, P., Pellegrini, R., Olivo, D., Colaci, M., Murdaca, G. |
|---|---|
| Přispěvatelé: | Ferri C., Giuggioli D., Raimondo V., Fallahi P., Antonelli A., Spinella A., Brittelli R., Aiello V., Caminiti R., L'Andolina M., Tavoni A., Bilia S., Giannini D., Mariano G.P., Cecchetti R., Guiducci S., Bellando-Randone S., Ursini F., Brusi V., Meliconi R., Caminiti M., Varcasia G., Ferrari T., Gigliotti P., Pellegrini R., Olivo D., Colaci M., Murdaca G. |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Pediatrics medicine.medical_specialty rheumatoid Population Immunology Arthritis autoimmune disease Disease Scleroderma General Biochemistry Genetics and Molecular Biology 03 medical and health sciences Psoriatic arthritis 0302 clinical medicine Rheumatology Pandemic medicine Immunology and Allergy autoimmune diseases scleroderma education Spondylitis 030203 arthritis & rheumatology education.field_of_study business.industry spondylitis systemic medicine.disease arthriti ankylosing arthritis psoriatic 030104 developmental biology spondyliti business Cohort study |
| Zdroj: | Annals of the Rheumatic Diseases |
| ISSN: | 1468-2060 0003-4967 |
| DOI: | 10.1136/annrheumdis-2020-219113 |
| Popis: | We followed with great interest the numerous reports published by the Annals 1–9 as regards the impact of the COVID-19 pandemic on different rheumatic autoimmune systemic diseases (ASD), including the survey study by Costa et al 9 that underlined the usefulness of telerheumatology in the management of patients with psoriatic arthritis in COVID-19 era. On the same topic, the world literature encompasses a large number of anecdotal observations, cohort studies and telephone surveys.1–15 Overall, the observed prevalence of symptomatic COVID-19, usually as mild-moderate disease, in patients with chronic arthritis was comparable to that found in the general population, while worse outcomes represented almost rare events.1–15 Conversely, increased percentages of symptomatic COVID-19 were observed in patient cohorts with connective tissue diseases, especially systemic lupus or systemic vasculitis.6 7 Of note, in ASD complicated by COVID-19, the baseline use of immune modifiers, namely, conventional synthetic (csDMARD), biological (bDMARD) and targeted synthetic disease-modifying antirheumatic drugs (tsDMARD), was not associated with worse COVID-19 disease outcomes.3–5 9 10 Almost invariably these monocentre studies focused on ASD patients’ populations from limited geographical areas.1–15 Given the heterogeneous distribution of pandemic infection within the same country, we investigated the impact of COVID-19 in ASD patients’ populations from three distinct regions of Italy (northern, Emilia Romagna; central, Tuscany; and southern, Calabria), characterised by different spread of the COVID-19 pandemic, prevalent in northern Italy with a marked gradient north-south.16 Our 6-week multicentre telephone survey of 1641 unselected patients with ASD confirmed the quite benign clinical course of COVID-19 in ASD, along with the safety of baseline use of either … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|